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Palavras-chave 
 
Estudo clínico, Coordenador de Investigação Clínica, Blueclinical, Estudos 
Observacionais 
 
Resumo 
 
 
O presente relatório descreve com detalhe as atividades e aprendizagens 
adquiridas no âmbito do meu estágio curricular como coordenador de estudos 
na Blueclinical, Lda., para obtenção do grau de mestre de Biomedicina 
Farmacêutica. 
 
De acordo com o tipo de serviços prestados, a Blueclinical pode ser dividida 
em três unidades de negócio: Blueclinical Clinical Research Partnership, 
Blueclinical Phase I e Blueclinical Research and Development. O facto de 
pertencer a esta companhia deu-me a oportunidade de estar em contacto com 
diferentes áreas do desenvolvimento farmacêutico e de contactar com 
diferentes equipas de investigação, o que para mim foi uma vantagem para a 
integração e consolidação de conhecimento, bem como para o 
desenvolvimento de hard e soft skills. 
 
A principal atividade desenvolvida foi a coordenação de estudos clínicos, na 
Unidade Local de Saúde de Matosinhos, E.P.E., que se insere na rede de 
hospitais que estabeleceram parceria com a Blueclinical, Lda. 
 
 
Durante o meu estágio pode contactar com diversas fases de coordenação e 
desenvolvimento de ensaios clínicos, que serão relatadas nesta dissertação.  
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Abstract 
 
The present report describes in detail the activities and knowledge aquired  
during my internship as study coordinator in Blueclinical – Investigação e 
Desenvolvimento em Saúde, Ltd., in order to obtain the master degree in 
Pharmaceutical Biomedicine.  
 
According to the type of services provided, Blueclinical is formed by three 
business units: Blueclinical Clinical Research Partnership, Blueclinical Phase I 
and Blueclinical Research and Development. The fact of belonging to such a  
company gave me the opportunity to be in touch with different areas of 
pharmaceutical development and to contact with different research teams, 
which for me was an added advantage to the integration and consolidation of 
knowledge, as well as in the development and improvement of soft and hard 
skills.  
 
The main activity developed was the coordination of clinical studies, in Unidade 
Local de Saúde de Matosinhos, E.P.E., which was one of the institutions that 
established a partnership with Blueclinical, Ltd.  
 
During my internship I was able to contact with various stages of development 
and coordination of clinical trials, which will be reported in this report. 
 
 
  
 
  
i 
 
TABLE OF CONTENTS 
1. Introduction ........................................................................................................................... 1 
1.1. Host company overview ........................................................................................................ 2 
1.1.1. Blueclinical Phase I ....................................................................................................... 2 
1.1.2. Blueclinical R&D .......................................................................................................... 3 
1.1.3. Blueclinical Clinical Research Partnership ................................................................... 3 
1.1.3.1. Unidade Local de Saúde de Matosinhos, E.P.E – Hospital Pedro Hispano ............ 5 
2. State-of-the-art ...................................................................................................................... 6 
2.1. Introduction to the R&D model for pharmaceutical products .......................................... 6 
2.2. Regulatory framework ....................................................................................................... 11 
2.3. Clinical trials coordination ............................................................................................... 14 
3. Experience as clinical study coordinator ............................................................................. 19 
3.1. Feasibilities and qualification visits .................................................................................... 19 
3.2. Study submission ................................................................................................................ 20 
3.3. Initiation visits ..................................................................................................................... 20 
3.4. Patients recruitment ............................................................................................................. 21 
3.5. Clinical visits ....................................................................................................................... 21 
3.6. Activities performed after the visits .................................................................................... 23 
3.7. Monitoring visits ................................................................................................................. 23 
3.8. General training ................................................................................................................... 24 
4. Discussion ........................................................................................................................... 25 
5. Conclusion ........................................................................................................................... 26 
6. Bibliography ........................................................................................................................ 27 
 
 
 
 
 
 
ii 
 
LIST OF FIGURES 
Figure 1 - Blueclinical's business units .............................................................................................. 2 
Figure 2 - Blueclinical CRP network ................................................................................................. 4 
Figure 3 - Correlation between development phases and types of study ........................................... 8 
Figure 4 - Critical path of drug development ..................................................................................... 9 
Figure 5 - The traditional paradigm vs. the “quick win, fast fail” paradigm.................................... 10 
 
  
iii 
 
LIST OF TABLES 
Table 1 - European and national regulatory framework for clinical research .................................. 12 
iv 
 
LIST OF ABBREVIATIONS 
  
AE  Adverse Event 
CEIC  Comissão Ética para a Investigação Clínica 
CNPD  Comissão Nacional de Proteção de Dados 
CPI  Critical Path Initiative  
CRA  Clinical Research Associate 
CRF  Case Report Form 
CRO  Clinical Research Organisation 
CRP  Clinical Research Partnership 
CS  Candidate Selection 
CV  Curriculum Vitae 
EC  European Commission 
EMA  European Medicines Agency 
FDA  Food and Drug Administration 
FED  First Efficacy Dose 
FHD  First Human Dose 
GACEC  Gabinete de Apoio ao Centro de Ensaios Clínicos 
GCP  Good Clinical Practice 
HPH  Hospital Pedro Hispano 
ICF  Informed Consent Form 
IMI  Innovative Medicines Initiative 
IMP  Investigational Medicinal Product 
INFARMED Instituto Nacional da Farmácia e do Medicamento  
IVRS  Interactive Voice Response System 
IWRS  Interactive Web Response System 
v 
 
LTD  Limited 
MS  Member State 
PD  Product Decision 
PI  Principal Investigator 
PoC  Proof of Concept 
p(TS)  Probability of Success 
R&D  Research and development 
SAM  Sistema de Apoio ao Médico  
SOP  Standard Operation Procedure 
ULSM  Unidade Local de Saúde de Matosinhos  
 
1 
 
1. INTRODUCTION 
My internship within the scope of the Pharmaceutical Biomedicine Master’s degree, 
at the University of Aveiro, took place at Blueclinical – Investigação e Desenvolvimento 
em Saúde, Ltd. The internship lasted 9 months and started on 1st August, 2013. 
Blueclinical includes three business units – Blueclinical Clinical Research 
Partnership, Blueclinical Research and Development and Blueclinical Phase I. My 
internship took place at Blueclinical Clinical Research Partnership, in Unidade Local de 
Saúde de Matosinhos, E.P.E. 
According with my expectations about the work, that I will describe later, and taking 
in to account the characteristics of the host company, I defined a set of primary and 
secondary objectives: 
 Develop a deep understanding about the regulatory framework of clinical trials and 
clinical studies;  
 Acquire skills, experience and know-how in clinical trials coordination; 
- Contact with the reality of a national research site; 
- Establish networking with peers, investigators, monitors, other professionals 
and institutions; 
 Develop interpersonal and soft skills; 
- Personal and professional development; 
 Consolidate the knowledge acquired throughout the academy. 
Regarding the report’s structure and contents, this work is divided into six chapters, 
containing several subchapters. Chapter 1 – Introduction, presents my internship objectives 
and the summary of the report, and the overview of Blueclinical’s structure, mission and 
services. Chapter 2 – State of the Art, includes the state of the art of the pharmaceutical 
research and development and the applicable European regulatory framework concerning 
the clinical investigation process. Chapter 3 – Experience as clinical study coordinator, 
describes the activities developed and the different training sessions and meetings 
attending. Chapter 4 – Discussion, where I describe in general terms the main difficulties 
felt and the learning outcomes achieved. The last chapter corresponds to the conclusion.  
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1.1. HOST COMPANY OVERVIEW 
Blueclinical – Investigação e Desenvolvimento em Saúde, Ltd. is a company that 
was created in May 2012 and whose headquarters are located at Avenida Villagarcia de 
Arosa, 1919, 4460-439 Senhora da Hora, Matosinhos (1). 
According to the type of services provided, Blueclinical is formed by three business 
units: Blueclinical Clinical Research Partnership (Blueclinical CRP), Blueclinical Phase I 
and Blueclinical Research and Development (Blueclinical R&D). As shown in Figure 1 the 
business units can provide a complete range of services and competencies that cover all 
phases of pharmaceutical research and development process, since preclinical development 
to commercialization (1). 
 
Figure 1 - Blueclinical's business units [Adapted from: (12)].  
 
1.1.1. BLUECLINICAL PHASE I 
Blueclinical Phase I consists in a Human Pharmacology Unit located in Hospital da 
Prelada, Porto.  
Blueclinical Phase I mission is the conduction of Phase I clinical trials, in healthy 
volunteers and in selected populations of patients (proof-of-concept studies). Its creation 
was based on the purpose of generating new opportunities at the clinical research level, 
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mainly in the early stages of the clinical development, and as a way of supporting other 
companies in the development of their programs (2,3). 
The clinical team is composed by the clinical director, a group of medical 
investigators and their coordinator - the principal investigator (PI), and also a team of 
nurses and their coordinator. The phase I team also includes laboratory technicians, one 
pharmacist and the clinical research manager (2,3). 
 
1.1.2. BLUECLINICAL R&D 
Blueclinical R&D is focused on providing consulting services in pharmaceutical, 
non-clinical, clinical, regulatory and commercial development.  
The R&D business unit pretends to fuel translation research in Portugal, supporting 
institutions and businesses, such as national and international start-ups, universities and 
other public or private institutions, in the development of their R&D projects with a view 
to the subsequent marketing (4).  
Blueclinical R&D provides expert advice on the preparation and implementation of 
pharmaceutical, preclinical, clinical and regulatory development plans of new drugs, 
medical devices and other health products; preparation and monitoring of scientific and 
regulatory advice; planning and supervision of pharmaceutical development and analytical 
methods; preparation of the Investigator’s Brochure and the Investigational Medicinal 
Product Dossier; portfolio selection support; analysis and support in the preparation of the 
business plan and application for funding (4,5). 
 
1.1.3. BLUECLINICAL CLINICAL RESEARCH PARTNERSHIP 
Blueclinical CRP intends to support the clinical research centres in Portugal, 
establishing partnerships with target national hospitals, promoting their growth, efficiency 
and excellence in clinical research, with drugs and medical devices (6). 
Blueclinical CRP mission is to support the activity of clinical research centres. It 
consists in the creation of Clinical Research Officers in the research centres, with 
professionals specialized in managing research sites. Therefore, it pretends to establish 
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partnerships with hospitals, enhancing their ability to carry out research of excellence 
through its operational management (6). 
All clinical research related activities are performed under a quality management 
system. This system aims to document and standardize, by means of written standard 
operating procedures (SOPs), all critical clinical research activities, in order to maximize 
the efficiency of the processes and to assure full compliance with good clinical practices 
(GCPs) and the legal and ethical requirements (6). 
Blueclinical CRP has a network of hospitals and primary care units, covering all 
therapeutic areas and a large population, which leads to fast study participants recruitment 
and a high number of patient referral from primary care units (6,7). 
The ultimate goal is to develop a network of highly effective clinical research sites. 
The Blueclinical CRP network is presented below on Figure 2. 
 
Figure 2 - Blueclinical CRP network (7) 
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This network can introduce Portugal as a competitor country within Europe, with 
investigational site of excellence, with dedicated and trained teams, and with more 
attractive times of regulatory approvals. 
 
1.1.3.1. UNIDADE LOCAL DE SAÚDE DE MATOSINHOS, E.P.E – 
HOSPITAL PEDRO HISPANO 
ULSM was established in 1999, and integrates Hospital Pedro Hispano (HPH) and 
Health Centers in Matosinhos, Senhora da Hora, Leça da Palmeira and São Mamede 
Infesta. Since 2007 integrates also a Convalescence Unit short and the plane of Public 
Health, called Centro de Sanidade e Fronteiras. ULSM is a reference of integration of 
primary, tertiary and continuing care at a national level (8).  
The ULSM, is governed by its statutes published on decree law 233/2005 of 29th 
December, amended and republished by amended by decree no. 244/2012, of 9th 
November, the legal regime applicable to E.P.E., as well as the special rules whose 
application result from its purposes and rules (8). 
The Mission of ULSM is to identify the health needs of the population in its area of 
influence. Provide a comprehensive, integrated and personalized service, with timely 
access, technical and scientific of excellence throughout the life cycle, creating a sense of 
bonding and trust in employees and patients (8). 
The Administration Board of ULSM assign to clinical research a high strategic 
importance. The objective of the collaboration between Blueclinical and ULSM is to 
implement an excellence clinical research office within the centre. 
 
During the internship I acquire some knowledge about every business area of 
Blueclinical, however my internship was conducted on Blueclinical CRP, where I work as 
study coordinator at ULSM.  
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2. STATE-OF-THE-ART 
This chapter describes the state of the pharmaceutical R&D. The present chapter 
pretends to provide the theoretical basis of this report, i.e. description of clinical research, 
clinical trials phases, and applicable legislation of pharmaceutical R&D. Although the law 
21/2014 as been approved after the end of my internship in this chapter I will also present a 
brief review of this regulation and the main changes that it presents.  
 
2.1. INTRODUCTION TO THE R&D MODEL FOR PHARMACEUTICAL 
PRODUCTS  
Is a fact that pharmaceutical products contributes to improve people’s quality of life 
and to extend life expectancy. The innovation in drug development is considered as central 
to increase quality, safety and efficacy of the healthcare (9,10). 
Pharmaceutical R&D is defined as the process of discovering, developing and 
introducing in the market new medicinal products (11). Thus, it is a process organized in 
phases, since drug discovery until post launch activities. Earlier identification of the 
characteristics of the investigational product (IP) and planning its development according 
to the required profile is essential to an efficient development (11,12). 
The R&D of pharmaceutical products begins with the understanding of the disease 
and their causes. After developing a deep understanding about the disease, the research 
team start looking for a lead target, which is some component involved in the biochemical 
pathways of pathophysiology of the disease that can be targeted and explored. The 
subsequent phase is the “target validation” which is done through the conduction of a 
series of experiments in living cells and animal models of disease. Then, with the target 
validation concluded, the research team starts to find/develop a series of molecules, called 
“lead compounds”, capable to interact with the selected target and cause the desired effect 
(12,13). 
To determine which lead compounds present the necessary characteristics to proceed 
to the clinical development phase, they are submitted to a series of tests, e.g. 
pharmacokinetics and toxicology tests. After this initial screening, the remaining 
molecules’ structure are optimised in order to improve their properties (13).  
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Before entering in clinical development, the compounds that arrived to this stage are 
tested in vitro and in vivo (animal studies) – the non-clinical development. The information 
obtained is used to estimate a safe starting dose and dose range for clinical trials (13). 
In order to bring the new drug to the market the sponsor has to prove its efficacy, 
safety and quality through a series of clinical trials. According to directive 2001/20/EC 
(14, p.23), clinical trials are “any investigation in human subjects intended to discover or 
verify the clinical, pharmacological and /or to identify any adverse reactions to one or 
more investigational medicinal product(s) and/or to study absorption, distribution, 
metabolism and excretion of one or more investigational medical product(s) with the object 
of ascertaining its (their) safety and/or efficacy.”.  
Traditionally the R&D model is described as a process divided in four sequential 
phases, based on “trial and error”. In practice, those phases are not sequential, in figure 1 
it’s possible to see that the phase of a clinical trial it’s characterized by its purpose, i.e. the 
objectives of the trial, so one type of trial could occur at different time points of the drug 
development process, or studies from different phases could take place at the same time. 
Thus, a classification system based study objectives was developed (Figure 3). This 
classification system is described below (15): 
 Human Pharmacology Studies (Phase I studies): Studies designed in 
order to estimate tolerability, characterize the pharmacokinetic and pharmacologic 
profile of the investigational medicinal product (IMP) and to identify drug interactions 
and the maximum tolerated dose. Usually these studies are conducted on healthy 
volunteers; 
 Therapeutic Exploratory studies (Phase II studies): Studies whose 
primary objective is to explore the therapeutic efficiency of the drug candidate in target 
patient population; generally this is sub-divided in: the phase IIa trials, that often use 
dose escalation designs for estimating the dose response, and phase IIb trials, that 
evaluate the efficacy of the drug candidate at the prescribed dose regimen; 
 Therapeutic Confirmatory studies (Phase III studies): Studies performed 
on larger patient population, which are designed to confirm that the drug is effective 
for use in the intended indication and population. The main selection criteria of these 
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studies are as similar as possible to the daily routine. The data generated will support 
the “prescribing information”; 
 Therapeutic Use studies (Phase IV studies): Studies conducted while the 
drug is already on the market, in order to provide further information on the therapeutic 
effectiveness in real life conditions. 
 
Figure 3 - Correlation between development phases and types of study (15) 
The traditional and sequential model for drug development is slow, expensive and 
shortly predictive of the true clinical effectiveness of the study drug. In order to improve 
the drug development and promote better medicines, were developed two international 
initiatives, “Critical Path Initiative” (CPI) from United States of America and “Innovative 
Medicines Initiative” (IMI) from Europe. IMI and CPI are mostly used by the countries 
where they were developed, however this initiatives can be implemented by different 
countries as they introduce some guidances to obtain a better performance in 
pharmaceutical R&D. This two initiatives presents a new R&D strategy that is focused in 
the study of the pathophysiology allowing the development of better compounds, using 
better targets and new biomarkers (9,10,16).  
CPI was developed by Food and Drug Administration (FDA), in 2004. This initiative 
combines efforts of the government, industry, academy and patients to increase efficiency 
and productivity of R&D processes, create an innovative science and reduce uncertainty, 
with the application of new scientific tools (Figure 4). CPI is based in 6 topics (16): 
 Better Evaluation Tools – Consists in the development and quantification of 
new biomarkers and disease models. The interest in the biomarkers lead to 
the development of “The Biomarker Consortium” at the Foundation for 
National Institutes of Health; 
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 Streamlining Clinical Trials – This topic introduces innovative and efficient 
and improved clinical endpoints, to assess improvement of health or the 
occurrence of adverse drug reactions; 
 Harnessing Bioinformatics – Introduces the use of mathematics, statistics, 
computational data analyses and biological data to develop robust computer 
models of the human physiology and diseases; 
 Moving the Manufacturing into the 21st Century – Improve efficiency and 
quality of manufacturing, using tools to identify and analyse critical products 
attributes; 
 Developing Products to Address Urgent Public Health Needs – Consists 
in the use of antibiotics and countermeasures to combat emerging infections 
and bioterrorism; 
 At-risk Populations – Paediatrics – development of therapies for children 
and adolescents. 
 
Figure 4 - Critical path of drug development (16) 
The IMI was developed by European Medicines Agency (EMA). Similarly, this 
initiative aims to promote a faster R&D of better medicines and improve cooperation and 
competition among pharmaceutical companies. This initiative consists in 4 pillars (9,10):  
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 Pillar I: Improve Predictivity of Drug Safety Evaluation; 
 Pillar II: Improve Predictivity of Drug Efficacy Evaluation; 
 Pillar III: Knowledge Management: improve information and data utilization; 
 Pillar IV: Education and Training: resolution of training gaps.   
This initiative pretends to introduce a new R&D strategy based on a better 
knowledge of the pathophysiology and epidemiology of diseases prior to initiation of the 
expensive development phases (9,10). 
Several cases of big failures during the late stages of the clinical development 
process have led to the creation of a new development model (Figure 5): the “quick-win, 
fast fail” paradigm.  
 
Figure 5 - The traditional paradigm vs. the “quick win, fast fail” paradigm (12)  
This new approach aims to reduce uncertainty in the early stages (phase I/IIa) 
through the use of new tools and strategies, before the expensive later development stages. 
A good example is the conduction of proof-of-concept (PoC) trials that will have the 
capacity of providing evidence that the molecular target is being hit and causing the 
desired physiological response. These studies are performed earlier in drug development. 
This will result in a small number of new molecular entities entering in late stages phases. 
However, those that advance have a much higher probability of success and introduction in 
the market of those that progress in the development increases substantially (advance of 
the new chemical entity with established efficacy and safety). The savings gained from 
preventing costly failures can then be re-invested to further enhance R&D productivity 
(12). 
CS: Candidate selection; 
FED: First efficacy dose; 
FHD: First human dose;  
PD: Product decision;  
POC: Proof of concept; 
p(TS): Probability of 
success.  
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2.2. REGULATORY FRAMEWORK 
Clinical research is an extremely regulated area, with a series of laws and ethical 
standards in place. Their main purposes are to protect the rights and integrity of patients 
and study volunteers and to guarantee a high quality of the data produced/collected (17).  
The first attempt to harmonise the clinical trials approval process occurred in May 
2004 with the implementation of directive 2001/20/EC, which institutes the requirement of 
a prior approval of the clinical trial from the national competent authority and the central 
ethics committee of the country where the trial was submitted (14).  
However, this directive did not provide the required level of harmonization. As 
consequence, the European Commission has classified the need for new legislation as a 
priority in order to re-establish Europe’s competitiveness in terms of clinical research. 
Thus, in July 2012 a legal proposal for Clinical Trial Regulation has been adopted (18).  
The main purpose of this directive is to facilitate the conduction of multicentre trials 
by creating a new and simplified authorization procedure, through the creation of the 
Common Technical Document, the submission dossier, which contains a general part with 
scientific information identical for all member states (MS). Another innovation of this 
directive is the creation of the “EU portal” (18).  
This regulation is expected to be effective in 2016, followed by a 3-year period 
during which both the directive 2001/20/EC and the regulation will be in place (18).  
The Directive 2005/28/EC established the principles and guidelines for GCP as 
regards to IMP for human use, as well as the requirements for authorisation of the 
manufacturing or importation of such products (19).   
The Portuguese regulatory framework for clinical research is composed by the law 
46/2004, which established the obligation of favourable opinion from the Comissão de 
Ética para a Investigação Clínica (CEIC) and authorisation from Autoridade Nacional do 
Medicamento e Produtos de Saúde I.P. (INFARMED) and from Comissão Nacional de 
Proteção de Dados (CNPD) (20). This law is a transposition from directive 2001/20/EC.  
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As a transposition from directive 2005/28/EC, the law-decree 102/2007 presents 
information regarding GCPs and requirements for authorisation of the manufacturing and 
importation of IMPs (21). 
The law-decree 67/98 regulates personal data protection. This law-decree provides 
information about protection of personal data on clinical trials and about personal data 
protection on non-interventional studies (22). 
On 3rd April 2014 a new national law was approved. This law pretends to revoke the 
law 46/2004. This new law pretends to foster and streamline the clinical research and 
improve the competitiveness of Portugal in this area in the European and global context. 
Some of the improvements of this is law is the creation of a more comprehensive and 
harmonised legal framework, creation a national registry of clinical trials (Registo 
Nacional de Estudos Clínicos - RNEC), and the creation of a national network of ethics 
committees (Rede Nacional de Comissões de Ética para a Saúde – RNCES) and the 
establishment of more competitive deadlines (23). 
Table 1 - European and national regulatory framework for clinical research 
 
National and international regulations and policies have been developed to ensure 
that clinical research is conducted according with strict scientific and ethical principles. 
The main European and national laws and regulations are presented in Table 1. 
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2.3. CLINICAL TRIALS COORDINATION 
Implementation and conduction of clinical trials involve a wide range of tasks and 
processes. Previous to conduction of clinical trials, they must be submitted to regulatory 
authorities. After approval and preparation of the study documents, trial initiation visit can 
be performed.  
The implementation of a clinical trial is a process that can be divided into three 
phases related to the regulatory authorities: before, during and after the submission of a 
clinical trial to the regulatory authorities.  
Before the submission of a clinical trial to the regulatory authorities, sponsor should 
make a previous evaluation of the centre, the qualification visit. The qualification visit is 
performed after the feasibility questionnaire and the confidentiality agreement were 
fulfilled by the investigator. The feasibility questionnaires intend to determine the viability 
of a clinical trial at the site and the recruitment potential of the centre. In the qualification 
visit the sponsor evaluates some fundamental parameters that could influence the 
conduction of the clinical trial (24).  
After the qualification visit the sponsor’s representative is responsible to send a 
report to the sponsor. The sponsor evaluates the centre according with the report and 
decides to select or not the centre to participate in the trial. If sponsor selects the centre the 
process of submission starts (24). 
In Portugal, the regulatory authorities responsible to evaluate the submission process 
of a clinical trial are: INFARMED; CNPD; and CEIC. At this stage, during the submission, 
I was responsible to collect the necessary documents to the submission. Some documents 
were prepared by Blueclinical, according to the national laws and regulations, to help in 
the submission process. These documents should be adapted to each trial, and signed and 
dated for each responsible, before send to the sponsor. The sponsor is responsible for 
submit this documents to the regulatory authorities. The study approval by the site 
administration board is also required and is established by a Financial Agreement. This 
agreement between the sponsor the site administration board and the Principal Investigator 
(PI) establishes the responsibilities of each part, terms of collaboration, requirements for 
payment and reimbursement, publication and intellectual property terms, indemnification 
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and insurance, subject injury coverage, grounds for termination of contract and possibility 
of amending contract terms in the future (23). 
After the centre had been approved by the regulatory authorities the sponsor can 
initiate the trial in the site. The trial is initiate by the initiation visit. This visit is performed 
by the sponsor’s representative, usually the clinical research associate (CRA) of the study, 
and it aims to leave the site totally able to initialize the recruitment for the clinical trial. 
During the initiation visit the CRA explains the study protocol, study procedures, case 
report form (CRF), adverse events (AEs) and serious adverse events (SAEs) notification 
procedure, investigation medicinal products that will be used in the trial, clinical reports 
and source documents, informed consent form (ICF) and biological samples to the research 
team. It is also important to fulfil the delegation log (document where the PI delegates 
some responsibilities of the trial to the other elements of the research team), and collect the 
curriculum vitae and training certificates, necessary to perform the activities of the trial, of 
all team members, this task can be done before this visit, during the submission process 
(24). 
Pharmacists, who are responsible for the storage, dispensing and accounting for 
experimental medicine, are trained by the CRA on the place and conditions of storage of 
the investigational product and completing the registration waiver and receiving the 
experimental drug, whose specifications are described in the protocol (24).  
To the research nurses, the CRA explain all clinical procedures described in the 
protocol applicable to the practice of nursing (24).  
Where there is shipment of biological samples to a central laboratory1, the CRAs are 
responsible for training the research members responsible for the preparation of laboratory 
kits, for the collection of biological samples, and for sending the samples, according with 
the laboratory manual of the study. Research teams should stay with all necessary 
instructions and documents for the handling and shipping of these samples (24).  
After the initiation visit the investigators can initiate the recruitment of participants 
to the trial. This period corresponds to the clinical phase of the clinical trial, where the 
                                                     
1 Central laboratories are chosen by the sponsor or their representatives, for the processing of biological 
samples of the clinical study, which can be analysed and processed using the same equipment with the same 
calibrations and if possible analysed by the same technician, ensuring the homogeneity and integrity of the 
results. 
16 
 
investigators identify and enrol participants who meet the eligibility criteria. Once 
identified potential participants, the research physicians must obtain the informed consent 
form from potential participants, before any trial procedure is performed. After sign the 
informed consent the participant are screened in order to ensure that they meet all 
eligibility criteria, and so they can be randomized to the trial, or is a screen failure. The 
eligibility criteria are established in the protocol, according with the objectives of the trial, 
and determine the criteria for the selection of participants for the study (21,25). 
If the subject fulfilled all the eligibility criteria, he/she can be randomized into the 
trial, the randomization is only applicable for randomized clinical trials. Randomization is 
the method of allocation of subjects to a treatment arm, randomly. This method allows to 
obtain comparable groups and to minimize possible bias. Randomization enables an 
equivalent distribution of subjects in the different treatment arms, thus producing a balance 
between the various factors that may influence the final results of clinical trials. 
Randomization is made using the interactive voice response (IVRS) or interactive web 
response system (IWRS). During the randomization call, an assignment of a subject 
identification number will be issued and the subject will be assigned to a treatment arm. In 
the case of non-randomized clinical trials the IVRS/IWRS is not used to assign the subject 
to the study drug (26,27).  
Randomization marks the beginning of the clinical phase of the trial. At this stage the 
treatment study visits begins, this visits are performed according to the study flow-chart 
established in the study protocol. All procedures required for each visit are presented in the 
schedule of assessments, which is an annex of protocol, and are detailed described at the 
body text of the protocol.  
In all visits it is necessary to use the IVRS or IWRS to assign the subsequent study 
drug kit numbers to the subject. IVRS/IWRS is also used to perform other procedures, such 
as: recording failures in the patient’s screening, obtaining subsequent drug assignment or a 
replacement kit, dose titration, discontinuing a patient, acknowledging study drug receipt, 
registration of an unscheduled visit, completion of a patient, resolution of temperature 
excursion and restarting a patient drug (26,27).  
Other important stage of coordinating clinical trials is the data entry on the CRF. 
This forms should be completed at the end of each study visit. eCRF aims to transmit all 
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the relevant information collected during the study to the sponsor and to the regulatory 
authorities (28).  
The close out visit of the study determines the end of the trial, and is performed after 
the completion of all the procedures of all subjects of the study, when the sponsor decides 
to finish the trial, or by request of investigator, CEIC/Local Ethics Committee or other 
regulatory authority.  The end of the trial must be notified to INFARMED, CEIC, CNPD 
and to the administration board of the study site within ninety days. If the trial ends 
prematurely the notification to regulatory authorities and administration board should be 
made within fifteen days after completion (24). 
This chapter gives the theoretical environment that supported my activities as study 
coordinator, which are described below in the next chapter. 
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3. EXPERIENCE AS CLINICAL STUDY COORDINATOR  
In this chapter I will describe my experience during my internship in Blueclinical as 
Study Coordinator. During this period I was allocated to the Clinical Research Office of 
Unidade Local de Saúde de Matosinhos, E.P.E. (ULSM) where I carried out Study 
Coordinator activities, from assessment, initiation and conduction of studies to its 
completion. 
The presentation of the Clinical Research Office (GACEC – Gabinete de Apoio ao 
Centro de Ensaios Clínicos) to the ULSM occurred on October 2014. In this meeting were 
presented the Blueclinical mission and objectives to the site personnel.   
 
3.1. FEASIBILITIES AND QUALIFICATION VISITS  
Blueclinical had a centralized process of feasibilities. Initially the feasibilities were 
sent to the Blueclinical headquarters and then they were distributed by the feasibilities 
specialist to the Blueclinical sites. Then the clinical research office, where I was inserted, 
was responsible to address the interest of the respective hospital service to conduct the 
study. Sometimes the sponsor or the Contract Research Organization (CRO) indicated the 
clinical research sites and investigators that appear to be the most suitable and interested 
for the conduction of the study. 
During my internship almost 70 feasibilities were submitted to ULSM. I was 
responsible to contact the respective services and to ensure that the feasibility was 
correctly fulfilled by the investigator. If the feasibility had questions related to support 
services, as pharmacy or imaging service, I was also responsible for contacting these 
services in order to answer those questions. 
After the feasibility some sponsors performed a qualification visit to verify the 
hospital facilities and if it was suitable to conduct the study. The qualification visits were 
scheduled by the clinical research office with every service involved in the study 
procedures.  
As study coordinator, I had to schedule this visits with the sponsor’s representative 
and with the respective services that could be involved in the trial. In this visits were 
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assessed the study site feasibility to conduct and carry out the clinical study, such as the 
human resources and infrastructures of the centre. 
I had participated in three qualification visits that resulted in the site selection.    
 
3.2. STUDY SUBMISSION 
Blueclinical had specific documents that were used in all submissions. At submission 
these documents were adapted to each trial and sent to the sponsor or sponsor’s 
representative, who prepared the submission file to submit the study to the administration 
board. 
Before sending the submission documents to the administration board, I reviewed the 
submission file in order to verify if the necessary documents were present. A checklist of 
all of the required documents was filled out. The submission file must include:  a cover 
letter; protocol updated version; protocol synopsis; site facilities; Portuguese or bilingual 
financial agreement signed and dated by the PI and the sponsor; sponsor declaration – 
proof that the trial was submitted to CEIC, INFARMED and CNPD. If all documents were 
present, I sent the submission file to the administration board for the final approval.  
In the submission process, my specific functions were to obtain the signed and dated 
financial agreements; send the approval craft to the CRA; and send two originals of the 
financial agreement to the CRA.  
 
3.3. INITIATION VISITS  
Initiation visits were always performed in-person. In these visits, I received adequate 
training on the protocol along with the research team (e.g. study objectives, ICF, AE/SAE 
reporting, GCP principles, study drug, CRF); some important documents were collected 
(e.g. subject pre-screening logs, delegation log); and the recruitment was discussed. In 
most cases, some documents were still missing, so I had to collect them and send them to 
the CRA (e.g. research team’s CV, delegation log, financial disclosure forms).  
During the curricular training period, I had the opportunity to be present at two 
initiation visits. 
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3.4. PATIENTS RECRUITMENT 
The recruitment period was established by the sponsor and was the time during 
which the investigators had the opportunity to recruit patients to the study. During this 
period, the investigators and I tried to select possible subjects to be included in the study. 
All weeks the pre-screening list, i.e. the list of potential participants was to be sent to the 
sponsor. The identification of potential participants was a fundamental task to ensure that 
the research team reached the number of proposed subjects. Depending of the study, 
potential participants were detected in the emergency service, inpatient, external 
consultations, or in patient’s databases.  
My work in patient’s selection was performed mainly in patient’s databases and 
Medical Support System (SAM) application. Furthermore, I also analysed the eligibility 
criteria with the investigator and, if applicable, screen and enrol the patient in the study. 
Compliance with all eligibility criteria is essential and it should be respected by all 
investigators. These criteria were established based on safety parameters that should be 
considered when including subjects to ensure their safety and well-being. 
 
3.5. CLINICAL VISITS 
Clinical visits period encompassed all activities related with patients, including 
preparation and conduction of the visits. 
The study visits were scheduled according to the study protocol, and every procedure 
for each visit was completed. So, the preparation of clinical visits was essential to 
guarantee compliance with all required procedures.  
Using the study flow-chart and visit plan, that resume the procedures involved in 
each visit, I prepared a worksheet to the investigator that schematized all visit procedures. 
The preparation of visits was performed taking into account specific procedures according 
to pathology, study phase, visit number and concomitant diseases and medications. 
However, generally some procedures were common to the most of the visits, and should be 
presented at the worksheet, such as: 
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 Measurement of vital signs; 
 Collection of biological samples; 
 Report of AEs; 
 Verification of concomitant medication and procedures; 
 IVRS/IWRS contact. 
When performing the worksheet I had also to carefully specify the tasks order and timing to 
perform the specific procedures, in order to guarantee that these timings were strictly complied. 
Additionally, I prepared all necessary forms (considered source documents) to 
register all clinical data, such as:  
 Pharmacy prescription form; 
 Nurse form; 
 Study visit script;  
 Questionnaires required by protocol; 
 Laboratory kits; 
 Materials for biological samples shipment (ambient temperature and/or dry 
ice). 
In visits that involved the collection of biological samples, I identified the laboratory 
tubes and completed the requisition form with patient’s number, date of birth, visit date 
and number of the visit. 
On the visit day, I was responsible to administer the study questionnaires to the 
patients in a reserved room, as this procedure should be performed before the consultation, 
and then to forward them to the medical office. During the consultation, the investigator 
evaluates the overall status of the patient and decided if the patient was able to continue in 
the study. If the patient continued in the trial, I called the IVRS/IWRS to request 
medication to the patient. After the call I received an e-mail of the application with the 
medication number. This e-mail was attached to the prescription form, and I was 
responsible to deliver these documents to the pharmaceutic of the study, and to ensure that 
they were achieved in the pharmacy file of the respective study. 
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At the end of the visit, I received patient´s bills and sent them by e-mail to the sponsor. The 
patient’s bills can’t have any identification. Before send the bills to the sponsor I had to identify 
them with the study number, patient’s study code and visit number. 
Monthly, a schedule of the planned visits was prepared and sent to the research 
teams. 
 
3.6. ACTIVITIES PERFORMED AFTER THE VISITS 
After the visit, I was responsible to review the source documents to guarantee that no 
errors were registered or if there is any missing information. The information collected 
during the visit will be transcribed into the CRF. If some information was not totally 
clarified, that should be clarified with the investigator, in order to correctly fill the CRF. 
Sometimes, I had to answer to queries generated by the CRA or data management of 
the study due to discrepancies in the data introduced. If necessary, these queries were 
clarified with the investigator. 
To maintain all study materials updated, after the visit, I organized all study materials 
on the right places. The stock of materials and laboratory kits were checked periodically. 
To avoid missing study material, I filled a template of kits accountability. 
 
3.7. MONITORING VISITS  
The monitoring visits pretended to perform source data verification to ensure that all 
data collected were reliable and that reconstruction and evaluation of the study was 
possible.  
I was responsible for schedule these visits with the research team, which involve 
different services, and prepare the materials needed to the visit, to make sure that the CRA 
had the necessary conditions to perform the visit.  
During the visit, the CRA verify the consistency between the CRF and source 
documents. Then, I had to correct all the issues identified by the CRA and, if applicable, 
clarify those issues with the investigator. 
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3.8. GENERAL TRAINING 
At the beginning of my training, I had the opportunity to attend to a training session 
at Blueclinical Phase I facilities focused in all Blueclinical business areas. In this training 
was possible to talk with people with more experience, which help me to understand and 
know how to overcome some issues that could affect me during my training.  
Before start my training, as study coordinator, I firstly researched and tried to 
understand the procedures involved in clinical research coordination. Since I was an intern 
at Blueclinical, but I was introduced in a place with different procedures, it was important 
to understand how to implement a new procedure at the hospital. So, I had a training 
session about all Blueclinical CRP SOPs that was to be implemented in the quality system 
of ULSM.  
After the implementation of the clinical research office at ULSM, I started to study 
the protocols of active studies. At this stage, the site had 2 active trials, in the oncology 
service. The protocol training was complemented with the training of the CRA.  
25 
 
4. DISCUSSION 
If basic training is important for good performance on internship, there is however a 
set of skills that have been acquired during the internship and difficulties felt associated 
with the type of tasks performed. 
During the nine months internship I developed technical and social skills that were 
crucial for entry into the work market. I developed technical skills at the level of 
coordination and conduction of clinical studies. In the submission of the studies was 
possible to contact with different services of the hospital and to know its facilities, and to 
different CRAs.  
Within the coordination of studies I had the opportunity to perform such diverse 
tasks as coordination of visits to the assessment of the site feasibility and early explanation 
of the study to the research team. During the conduction of the study I was also responsible 
to support the research team in every task related to the study. Since I had to have a 
thorough knowledge about the study I learned about different diseases and different 
therapeutic areas, such as: oncology, neurology, nephrology, cardiology, gastroenterology, 
gynecology and obstetrics. 
Finally, and still talking about acquired skills, I can emphasize social skills. I 
developed autonomy, confidence and ability to manage the time, since I need to establish 
priorities according with the various projects taking place in parallel with specific 
timelines. The interaction with various research teams, as well as contact with the various 
realities allowed me to acquire social skills that I consider an asset for my future as 
proactivity, versatility, strategic vision and the ability to resolve conflicts. 
The ability to identify and apply the knowledge acquired throughout my learning 
experience as study coordinator was one of the biggest challenges.  
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5. CONCLUSION 
This report aimed to presenting the activities performed during my internship at 
Blueclinical, as well as learning outcomes and skills acquired during this period.  
This experience was very useful, and allowed the application of the knowledge 
acquired during the Bachelor of Biomedical Science and MSc in Pharmaceutical 
Biomedicine in real-life and concrete situations in the area of clinical research.  
I had the opportunity to perform various functions autonomously, which made the 
stage even more enriching. I learned how to coordinate and organize clinical trials since its 
initial stage to its completion. Thus, I consider that the originally proposed objectives were 
fully achieved.  
I can conclude that my academic training contributed to a good performance in 
various activities performed during the internship. The flexibility and autonomy that I 
acquired during academic training were quite useful during this period.  
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